Education
About Us
Working with TipRanks
Follow Us
Contineum Therapeutics, Inc. Class A (CTNM)
NASDAQ:CTNM
RESEARCH TOOLSreports
Total Valuation
Contineum Therapeutics, Inc. Class A has a market cap or net worth of $110.99M. The enterprise value is $519.78M.
Market Cap$110.99M
Enterprise Value$519.78M
Share Statistics
Contineum Therapeutics, Inc. Class A has 19,142,378 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding19,142,378
Owned by Insiders0.97%
Owned by Institutions<0.01%
Financial Efficiency
Contineum Therapeutics, Inc. Class A’s return on equity (ROE) is -0.21 and return on invested capital (ROIC) is -24.73%.
Return on Equity (ROE)-0.21
Return on Assets (ROA)-0.20
Return on Invested Capital (ROIC)-24.73%
Return on Capital Employed (ROCE)-0.25
Revenue Per Employee0.00
Profits Per Employee-1.03M
Employee Count41
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Contineum Therapeutics, Inc. Class A is -6.71. Contineum Therapeutics, Inc. Class A’s PEG ratio is 0.36.
PE Ratio-6.71
PS Ratio0.00
PB Ratio-4.15
Price to Fair Value1.43
Price to FCF-19.12
Price to Operating Cash Flow-19.23
PEG Ratio0.36
Income Statement
In the last 12 months, Contineum Therapeutics, Inc. Class A had revenue of 0.00 and earned -42.26M in profits. Earnings per share was -2.18.
Revenue0.00
Gross Profit0.00
Operating Income-50.89M
Pretax Income-42.26M
Net Income-42.26M
EBITDA-42.00M
Earnings Per Share (EPS)-2.18
Cash Flow
In the last 12 months, operating cash flow was -39.14M and capital expenditures -414.00K, giving a free cash flow of -39.56M billion.
Operating Cash Flow-39.14M
Free Cash Flow-39.56M
Free Cash Flow per Share-2.07
Dividends & Yields
Contineum Therapeutics, Inc. Class A pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.74
52-Week Price Change-81.45%
50-Day Moving Average4.18
200-Day Moving Average10.93
Relative Strength Index (RSI)41.24
Average Volume (3m)110.68K
Important Dates
Contineum Therapeutics, Inc. Class A upcoming earnings date is Aug 19, 2025, TBA Not Confirmed.
Last Earnings DateMay 14, 2025
Next Earnings DateAug 19, 2025
Ex-Dividend Date―
Financial Position
Contineum Therapeutics, Inc. Class A as a current ratio of 20.69, with Debt / Equity ratio of -148.40%
Current Ratio20.69
Quick Ratio20.69
Debt to Market Cap0.02
Net Debt to EBITDA0.37
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Contineum Therapeutics, Inc. Class A has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Contineum Therapeutics, Inc. Class A EV to EBITDA ratio is -6.38, with an EV/FCF ratio of -8.03.
EV to Sales0.00
EV to EBITDA-6.38
EV to Free Cash Flow-8.03
EV to Operating Cash Flow-8.15
Balance Sheet
Contineum Therapeutics, Inc. Class A has $190.71M in cash and marketable securities with $6.00M in debt, giving a net cash position of -$184.71M billion.
Cash & Marketable Securities$190.71M
Total Debt$6.00M
Net Cash-$184.71M
Net Cash Per Share-$9.65
Tangible Book Value Per Share$10.23
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Contineum Therapeutics, Inc. Class A is $24.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$24.67
Price Target Upside527.74% Upside
Analyst ConsensusStrong Buy
Analyst Count4
Revenue Growth Forecast-100.00%
EPS Growth Forecast-244.85%